Jazz Pharmaceuticals PLC $JAZZ Stock Acquired by Calamos Advisors LLC

Key Points

• Calamos Advisors increased its Jazz Pharmaceuticals stake by 764.2% in the third quarter, adding 10,935 shares to hold 12,366 shares valued at approximately $2.86 million.
• Jazz reported quarterly revenue of $1.24 billion, above the $1.21 billion consensus estimate and up 10.4% year over year; earnings per share also beat expectations.
• Analyst sentiment was broadly positive: the stock had a “Moderate Buy” consensus rating and an average price target of $293.45. Institutional investors owned 89.14% of shares.

Calamos Advisors LLC grew its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 764.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,366 shares of the specialty pharmaceutical company's stock after acquiring an additional 10,935 shares during the quarter. Calamos Advisors LLC's holdings in Jazz Pharmaceuticals were worth $2,863,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in JAZZ. USA Financial Formulas purchased a new stake in shares of Jazz Pharmaceuticals during the 1st quarter worth $25,000. Pension & Wealth Management Advisors Inc. purchased a new position in Jazz Pharmaceuticals in the third quarter valued at about $32,000. Ameritas Advisory Services LLC purchased a new position in Jazz Pharmaceuticals in the second quarter valued at about $47,000. Westpac Banking Corp bought a new position in Jazz Pharmaceuticals in the first quarter worth about $51,000. Finally, Elevation Wealth Partners LLC raised its holdings in Jazz Pharmaceuticals by 156.4% in the third quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company's stock worth $60,000 after purchasing an additional 158 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on JAZZ shares. Citigroup assumed coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, September 30th. They set a "buy" rating and a $325.00 price target for the company. TD Cowen lifted their price objective on shares of Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a "buy" rating in a research report on Tuesday, August 4th. UBS Group boosted their price objective on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the stock a "buy" rating in a research note on Friday, September 11th. JPMorgan Chase & Co. boosted their price objective on shares of Jazz Pharmaceuticals from $300.00 to $310.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 3rd. Finally, Barclays increased their target price on shares of Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an "overweight" rating in a research report on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $293.45.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $234.76 on Monday. The stock's fifty day moving average price is $229.39 and its 200 day moving average price is $217.74. Jazz Pharmaceuticals PLC has a 1-year low of $128.80 and a 1-year high of $266.38. The company has a market cap of $15.07 billion, a price-to-earnings ratio of 79.85, a price-to-earnings-growth ratio of 0.43 and a beta of 0.38. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.82 and a quick ratio of 1.64.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, topping the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.21 billion. During the same quarter last year, the company earned $8.13 earnings per share. The company's quarterly revenue was up 10.4% on a year-over-year basis. On average, research analysts expect that Jazz Pharmaceuticals PLC will post 11.08 earnings per share for the current fiscal year.

Insider Activity

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the business's stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $250.13, for a total transaction of $1,500,780.00. Following the sale, the director owned 351,875 shares of the company's stock, valued at approximately $88,014,493.75. The trade was a 1.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the company's stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the transaction, the executive vice president owned 65,686 shares in the company, valued at $16,401,794.20. The trade was a 53.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 102,534 shares of company stock valued at $25,185,243. 4.10% of the stock is owned by company insiders.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.